known as lupus nephritis. Visit our Lupus Nephritis Information Center to learn about symptoms, diagnosis, and treatment options. Visit the Lupus Nephritis Information Center Close WEBINAR: What You ...
In standing together, we can ensure that Mercédi’s fight with lupus is not her fight alone. A community mobilised by empathy ...
In standing together, we can ensure that Mercédi’s fight with lupus is not her fight alone. A community mobilised by empathy ...
Chimeric antigen receptor T-cell therapy improves not only lupus disease activity but also other related conditions that ...
US FDA accepts Roche’s Gazyva/Gazyvaro sBLA for the treatment of lupus nephritis: Basel Thursday, March 6, 2025, 09:00 Hrs [IST] Roche announced that the US Food and Drug Admini ...
Submission is supported by positive results from the Phase III REGENCY trial, which demonstrated that nearly half of patients ...
The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of ...
Roche's filing is based on data from a late-stage study that shows a complete renal response benefit in lupus nephritis patients who received Gazyva.
Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...
Genentech, a Roche Group company(OTCQX:RHHBY) said on Wednesday that the U.S. FDA accepted the company’s supplemental ...
The US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for ...
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback